Labcorp Holdings Inc. (LH) Stock Price & How to Invest

Labcorp Holdings is a leading US healthcare diagnostics company that runs clinical laboratory tests for physicians, hospitals, health systems, and patients, and also provides laboratory services to pharmaceutical and biotech firms running clinical trials. Its two reporting segments are Labcorp Diagnostics, the routine and specialty testing business that processes millions of patient samples, and Labcorp Biopharma Laboratory Services, which supports drug development with central-lab and early-development testing. Alongside domestic rival Quest Diagnostics, Labcorp is one of the two dominant independent lab networks in the country. The company spun off its clinical-trial contract-research organization, Fortrea, in 2023 to focus on core testing.

The investment picture is that of a defensive, cash-generative healthcare company rather than a high-growth name. Full-year 2025 revenue was about $13.95 billion with net income near $877 million, and management raised 2026 guidance to roughly $14.6 billion to $14.8 billion in revenue and adjusted EPS of about $17.70 to $18.35. Growth comes from mid-single-digit organic testing gains, tuck-in acquisitions of hospital outreach labs, specialty and genomic test menus, and steady biopharma demand, while free cash flow funds a dividend and share buybacks. The trade-off is exposure to reimbursement rates, payer mix, and regulatory pricing that can cap the upside.

Labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing. Payer mix and volume shifts, including the rise of at-home and point-of-care testing, could erode walk-in and routine-test revenue over time. The business is capital and labor intensive, so wage inflation and integration costs from acquisitions can weigh on margins. Biopharma demand is tied to pharma R&D budgets and clinical-trial activity, which can soften in a funding downturn. Regulatory changes around laboratory-developed tests and ongoing competition from Quest Diagnostics and hospital systems add further uncertainty.

16 analysts publish price targets on LH, averaging $341.50 against a $327.61 price as of September 2026, or +4.2%. The published targets run from $293.00 to $385.00, a narrow spread, and the ratings split 13 buy, 4 hold, 1 sell. Over the last six months there have been 8 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full LH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Labcorp Holdings Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Recurring diagnostics volume and scale. Labcorp Diagnostics processes an enormous, recurring stream of routine and specialty tests, which gives the company predictable demand that is relatively insulated from the economic cycle. The most optimistic published target, $385.00, assumes this works close to its best case.

The case against. Labcorp's biggest risk is reimbursement pressure, since a large share of revenue depends on rates set by Medicare, Medicaid, and commercial payers, and legislated fee cuts under frameworks like PAMA can compress pricing. The most pessimistic target, $293.00, is roughly what LH is worth if this bites instead.

Read the full bull and bear case on LH, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Labcorp Holdings Inc. (LH) has had one share split in the last 10 years:

• 1164:1000 on July 3, 2023, so every share held became 1.164 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of LH the day before the 1164:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Labcorp Holdings Inc.'s investor relations page or your broker.

• Revenue (FY2025): ~$13.95 billion
• Revenue guidance (FY2026): ~$14.6-14.8 billion
• Net income (FY2025): ~$877 million
• Adjusted EPS guidance (FY2026): ~$17.70-18.35
• Market cap: ~$24 billion
• P/E (trailing / forward): ~26x / ~16x

As of July 2026 Labcorp traded near $296 per share for a market cap around $24 billion, close to a 52-week high. The trailing P/E near 26x compresses to roughly 16x on 2026 adjusted EPS guidance, a valuation that sits below many healthcare peers. That reflects steady mid-single-digit revenue growth rather than rapid expansion, plus a modest dividend and buyback program.

If you want LH exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to LH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get LH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FVD), which spreads the position across many companies. Or build it into a focused thematic portfolio, so LH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where LH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Labcorp is a defensive large-cap diagnostics operator whose investment picture rests on recurring testing volume, hospital-lab acquisitions, and margin expansion, with reimbursement pressure and payer dynamics as the main offsetting risks.

Whether LH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LH a buy or a sell?, and where the stock could go from here in the LH stock forecast.

For income investors, whether LH pays a dividend and how the payout looks is covered in does LH pay a dividend? And to weigh LH against a peer, read the full side-by-side comparisons: LH vs DGX and LH vs ABT.